341 related articles for article (PubMed ID: 32329194)
1. Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT).
Gao L; Zhang P; Weng J; Lu J; Guo X; Jia W; Yang W; Zou D; Zhou Z; Pan C; Gao Y; Li X; Zhu D; Wu Y; Garg SK; Ji L
J Diabetes; 2020 Sep; 12(9):668-676. PubMed ID: 32329194
[TBL] [Abstract][Full Text] [Related]
2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of type 2 diabetes patients with discordance between HbA
Shu H; Lu J; Zhang P; Zhu D; Li X; Ji J; Zhao F; Ji L
Diabetes Metab Res Rev; 2018 May; 34(4):e2977. PubMed ID: 29314667
[TBL] [Abstract][Full Text] [Related]
4. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
Zhang B; Zhao J; Yang W;
Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
[TBL] [Abstract][Full Text] [Related]
5. Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline Characteristics.
Ji L; Zhang P; Weng J; Lu J; Guo X; Jia W; Yang W; Zou D; Zhou Z; Pan C; Gao Y; Li X; Zhu D; Li Y; Wu Y; Garg SK
Diabetes Technol Ther; 2015 Oct; 17(10):735-44. PubMed ID: 26171728
[TBL] [Abstract][Full Text] [Related]
6. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China.
Ji L; Zhang P; Zhu D; Li X; Ji J; Lu J; Guo X; Jia W; Weng J; Wu Y; Yang W; Zou D; Zhou Z; Pan C; Gao Y; Garg SK
Diabetes Obes Metab; 2017 Jun; 19(6):822-830. PubMed ID: 28105735
[TBL] [Abstract][Full Text] [Related]
7. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
Kvapil M
Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
[TBL] [Abstract][Full Text] [Related]
8. A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin.
Raccah D; Chou E; Colagiuri S; Gaàl Z; Lavalle F; Mkrtumyan A; Nikonova E; Tentolouris N; Vidal J; Davies M
Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27606888
[TBL] [Abstract][Full Text] [Related]
9. Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors.
Zhang T; Ji L; Gao Y; Zhang P; Zhu D; Li X; Ji J; Zhao F; Zhang H; Guo X
Diabetes Technol Ther; 2017 Nov; 19(11):675-684. PubMed ID: 29090977
[TBL] [Abstract][Full Text] [Related]
10. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).
Liu J; Jiang X; Xu B; Wang G; Cui N; Zhang X; Liu J; Mu Y; Guo L
Adv Ther; 2020 Apr; 37(4):1675-1687. PubMed ID: 32130661
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of basal insulin therapy in type 2 diabetes mellitus patients with or without metformin observed in a national cohort in China.
Zhang P; Chen M; Zhang H; Luo Y; Zhu D; Li X; Ji J; Wang D; Duolikun N; Ji L
BMC Endocr Disord; 2022 Jan; 22(1):26. PubMed ID: 35045841
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and safety of different basal insulins in a real-world setting.
Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
[TBL] [Abstract][Full Text] [Related]
14. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
Abitbol A; Brown RE; Jiandani D; Sauriol L; Aronson R
Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
[TBL] [Abstract][Full Text] [Related]
15. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III).
Li L; Yang T; Xue Y; Ruan P; Du J; Li Y; Zhang X; Cui N; Yang W
Adv Ther; 2022 Jan; 39(1):421-429. PubMed ID: 34757600
[TBL] [Abstract][Full Text] [Related]
16. Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients.
Siegmund T; Pfohl M; Forst T; Pscherer S; Bramlage P; Foersch J; Borck A; Seufert J
Diabetes Metab Syndr; 2017; 11(1):51-57. PubMed ID: 27578616
[TBL] [Abstract][Full Text] [Related]
17. Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study.
Vichayanrat A; Matawaran BJ; Wibudi A; Ferdous HS; Aamir AH; Aggarwal SK; Bajpai S
J Diabetes; 2013 Sep; 5(3):309-18. PubMed ID: 23462227
[TBL] [Abstract][Full Text] [Related]
18. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
19. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
20. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
